# OnCo record nct06395103 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06395103/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06395103", "NCT06395103" ;
  schema:name "Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)"@en ;
  schema:alternateName "LIGHTBEAM-U01"@en ;
  schema:description "A phase 1/2 trial of Zilovertamab vedotin in diffuse large b-cell lymphoma and burkitt lymphoma, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06395103/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06395103> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-08-16" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/ewing-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/zilovertamab-vedotin/> ;
  onco:companies <https://onco.cc/companies/merck/> .